tradingkey.logo

Novo rises as Eli Lily drug's efficacy soothes concerns over CagriSema

ReutersDec 11, 2025 3:11 PM

Shares in Novo Nordisk NOVOb.CO rise more than 3% in late afternoon trade after Eli Lilly LLY.N study's results on the efficacy of its next generation obesity drug retatrutide

J.P,Morgan says the drug's efficacy seems similar; retatrutide achieved a 23.7% weight loss on an intention-to-treat basis, roughly 3% higher than Novo's CagriSema

Kepler Cheuvreux deems the results "very mixed", which might be some relief to investors as Novo expectations have been very low

Nordnet also points out Wednesday's introduction of the “Safeguarding Americans from Fraudulent and Experimental Drugs Act of 2025" bill in the U.S., which is intended to protect patients, but will also potentially protect drug manufacturers

Novo Nordisk shares have lost about 49% YTD

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.
Tradingkey

Related Articles

Tradingkey
KeyAI